Physician profile
Ali I Amjad
NPI 1568690287
$1,314.62
in general payments reported to CMS, 2019-2025
18 companies · $50.30 in 2025
The $50.30 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $134 · 2021: $291 · 2022: $81.08 · 2023: $92.16 · 2024: $310 · 2025: $50.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411 · Education: $40.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.13 |
| Education | $40.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $524.29 | 2019-2022 | |
| Inari Medical, INC. | $252.65 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $251.33 | 2019-2025 | Opdivo |
| Myovant Sciences INC. | $47.86 | 2021-2022 | |
| Incyte Corporation | $39.72 | 2024-2025 | Jakafi, Niktimvo |
| Beigene USA, INC. | $32.23 | 2021-2022 | |
| Novo Nordisk INC | $29.51 | 2021-2023 | |
| Tempus Ai, INC | $29.29 | 2024 | |
| Sumitomo Pharma America, INC. | $23.93 | 2023 | Orgovyx |
| Shield Therapeutics INC | $20.86 | 2024 | |
| Karyopharm Therapeutics INC. | $19.32 | 2024 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Chiesi USA, INC. | $15.11 | 2025 | Cleviprex |
| Pfizer INC. | $11.50 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Amjad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.